116 related articles for article (PubMed ID: 9350218)
1. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas.
Jansson A; Sun XF
APMIS; 1997 Sep; 105(9):730-4. PubMed ID: 9350218
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma.
Nabi U; Nagi AH; Sami W
J Ayub Med Coll Abbottabad; 2008; 20(4):44-8. PubMed ID: 19999202
[TBL] [Abstract][Full Text] [Related]
3. Stereologic estimates of volume-weighted mean nuclear volume in colorectal adenocarcinoma: correlation with histologic grading, Dukes' staging, cell proliferation activity and p53 protein expression.
Martín R; Nieto S; Santamaría L
Gen Diagn Pathol; 1997 Jul; 143(1):29-38. PubMed ID: 9269906
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
7. ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma.
Sun XF; Wingren S; Carstensen JM; Stål O; Hatschek T; Boeryd B; Nordenskjöld B; Zhang H
Eur J Cancer; 1991; 27(12):1646-9. PubMed ID: 1782077
[TBL] [Abstract][Full Text] [Related]
8. Proliferative, infiltrative, and metastatic activities in colorectal tumors assessed by MIB-1 antibody.
Ishida H; Sadahiro S; Suzuki T; Ishikawa K; Kamijo A; Tajima T; Makuuchi H; Murayama C
Oncol Rep; 2003; 10(6):1741-5. PubMed ID: 14534689
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical assessment of growth fractions in colorectal adenocarcinomas with monoclonal antibody Ki-67. Relation to clinical and pathological variables.
Lanza G; Cavazzini L; Borghi L; Ferretti S; Buccoliero F; Rubbini M
Pathol Res Pract; 1990 Oct; 186(5):608-18. PubMed ID: 2287588
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis in relation to proliferating cell nuclear antigen and Dukes' stage in colorectal adenocarcinoma.
Evertsson S; Bartik Z; Zhang H; Jansson A; Sun XF
Int J Oncol; 1999 Jul; 15(1):53-8. PubMed ID: 10375593
[TBL] [Abstract][Full Text] [Related]
11. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis.
Kubota Y; Petras RE; Easley KA; Bauer TW; Tubbs RR; Fazio VW
Cancer; 1992 Dec; 70(11):2602-9. PubMed ID: 1423188
[TBL] [Abstract][Full Text] [Related]
12. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67.
Hemming AW; Davis NL; Kluftinger A; Robinson B; Quenville NF; Liseman B; LeRiche J
J Surg Oncol; 1992 Nov; 51(3):147-52. PubMed ID: 1434639
[TBL] [Abstract][Full Text] [Related]
13. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas.
Sen A; Mitra S; Das RN; Dasgupta S; Saha K; Chatterjee U; Mukherjee K; Datta C; Chattopadhyay BK
Indian J Pathol Microbiol; 2015; 58(2):158-62. PubMed ID: 25885126
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas.
Sahin AA; Ro JY; Brown RW; Ordonez NG; Cleary KR; el-Naggar AK; Wilson P; Ayala AG
Mod Pathol; 1994 Jan; 7(1):17-22. PubMed ID: 8159647
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas.
Stanton KJ; Sidner RA; Miller GA; Cummings OW; Schmidt CM; Howard TJ; Wiebke EA
Am J Surg; 2003 Nov; 186(5):486-92. PubMed ID: 14599612
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma.
Furudoi A; Tanaka S; Haruma K; Yoshihara M; Sumii K; Kajiyama G; Shimamoto F
Oncology; 2001; 60(2):162-9. PubMed ID: 11244332
[TBL] [Abstract][Full Text] [Related]
17. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
19. Sialyl Tn is a frequently expressed antigen in colorectal cancer: No correlation with patient prognosis.
Lundin M; Nordling S; Roberts PJ; Lundin J; Carpelan-Holmström M; von Boguslawsky K; Haglund C
Oncology; 1999 Jul; 57(1):70-6. PubMed ID: 10394128
[TBL] [Abstract][Full Text] [Related]
20. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival.
Lanza G; Maestri I; Dubini A; Gafa R; Santini A; Ferretti S; Cavazzini L
Am J Clin Pathol; 1996 May; 105(5):604-12. PubMed ID: 8623770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
